Lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia (BpALL) with chromosomal hyperdiploidy and with translocations affecting chromosome 12p11-13, accumulate high and low levels of methotrexate polyglutamates (MTXPGs), respectively. Recently a cryptic translocation, t(12;21) (p13;q22), has been demonstrated by molecular and fluorescence in situ hybridization techniques in this disease. The chimeric TEL-AML1 transcript, which has been associated with this translocation, can be detected in up to 25% of children with BpALL. We detected the TEL-AML1 and/or the AML1-TEL transcript in 30 (33%) of 91 patients studied. Levels of lymphoblast MTXPGs were lower in those with than in those without the TEL-AML1 translocation (P = 0.004). Hyperdiploidy was rare in lymphoblasts with the TEL-AML1 translocation (P = 0.047). Both ploidy (P= 0.0015) and TEL-AML1 status (P= 0.0043) were independently and significantly correlated with the log of the lymphoblast MTXPG level. However, the presence of TEL-AML1 or of hyperdiploidy accounted for only 22% of the variation of this value. Our results imply that each of 1.16 > or = DI and the presence of the TEL-AML1 translocation confers a 50% decrease in lymphoblast MTXPG level. When planning reduction of therapy for either of the two excellent outcome categories of hyperdiploid or TEL-AML1 BpALL, one should consider the difference between these two subgroups in the ability of lymphoblasts to accumulate MTXPGs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.leu.2402165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential molecular mechanisms of ETV6-RUNX1-positive B progenitor cell cluster in acute lymphoblastic leukemia revealed by single-cell RNA sequencing.
PeerJ
November 2024
Neurosurgery Department, Jinzhou Central Hospital, Jinzhou, China.
Article Synopsis
- The study aimed to investigate the immune landscape and immune cell roles in the progression of acute lymphoblastic leukemia (ALL), focusing particularly on the ETV6-RUNX1 genetic alteration common in childhood cases.
- Using advanced techniques like single-cell RNA sequencing, researchers analyzed B progenitor cells from bone marrow samples, identifying specific gene expressions and pathways that may drive rapid cell cycle progression in ALL.
- Results highlighted distinct clusters of B progenitor cells, particularly one with amplified genes on chromosome 6p that were linked to increased cell cycle activity, underscoring the complexity of immune interactions in the disease's progression.
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
Blood
January 2025
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI) risk classification, except when there is slow minimal residual disease (MRD) response or central nervous system/testicular involvement.
View Article and Find Full Text PDFETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Leukemia
July 2024
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Article Synopsis
- Recent trials show that over 95% of kids with a specific type of leukemia called ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL) live for at least 5 years after treatment.
- Scientists looked at different drug doses and their effects on patients from various studies to see how they compare and to better understand what treatment works best.
- The results suggest that some patients could possibly receive less intensive treatment while still being treated effectively, so future research should explore the possibility of giving less medicine.
B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/β response in bone marrow-derived mesenchymal stroma.
Haematologica
July 2024
Dept. of Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) can hijack the normal bone marrow microenvironment to create a leukemic niche which facilitates blast cell survival and promotes drug resistance. Bone marrow-derived mesenchymal stromal cells (MSC) mimic this protective environment in ex vivo co-cultures with leukemic cells obtained from children with newly diagnosed BCP-ALL. We examined the potential mechanisms of this protection by RNA sequencing of flow-sorted MSC after co-culture with BCP-ALL cells.
View Article and Find Full Text PDFOutcome and Prognostic Factors of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia.
Acta Haematol
September 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences, Beijing, China.
Introduction: The role of haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) in pediatric patients with relapsed or refractory (R/R) ETV6/RUNX1-positive acute lymphoblastic leukemia (ALL) is unclear. This study aimed to identify prognostic factors and explore the role of haplo-HSCT in the treatment of ETV6/RUNX1-positive ALL.
Methods: We analyzed the clinical characteristics and treatment outcomes of 20 pediatric patients who were diagnosed with ETV6/RUNX1-positive ALL and received chemotherapy/chimeric antigen receptor T-cell bridged to haplo-HSCT between 2016 and 2021 at our institution.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!